20532-39-2

Basic information

• Product Name: benzo[b]thiophene-5-carboxylic acid methyl ester
• Synonyms: benzo[b]thiophene-5-carboxylic acid methyl ester;methyl benzo[b]thiophene-5-carboxylate
• CAS NO: 20532-39-2
• Molecular Formula: C₁₀H₈O₂S
• Molecular Weight: 192.23432
• Mol File: 20532-39-2.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• CAS DataBase Reference: benzo[b]thiophene-5-carboxylic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: benzo[b]thiophene-5-carboxylic acid methyl ester(20532-39-2)
• EPA Substance Registry System: benzo[b]thiophene-5-carboxylic acid methyl ester(20532-39-2)

Safety Data

• Hazardous Substances Data: 20532-39-2(Hazardous Substances Data)

Upstream product

• 2060-63-1 benzo[b]thiophene-5-carbonitrile 
• 4923-87-9 5-bromobenzo[b]thiophene 
• 2060-64-2 benzo[b]thiophene-5-carboxylic acid 
• 67-56-1 methanol 
• 1266327-49-4 2-trimethylsilylethynylthiophene-3-carbaldehyde 
• 2365-48-2 Methyl thioglycolate 
• 112101-59-4 methyl 6,7-dihydrobenzothiophene-5-carboxylate 

Downstream Products

• 1005206-97-2 methyl 3-bromo-1-benzothiophene-5-carboxylate 

Relevant articles and documents

NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS

The present invention relates to novel dihydropyridine derivatives of formula (I): as modulators of nuclear receptors selected from androgen receptor and glucocorticoid receptor, to processes for their preparation, to pharmaceutical compositions comprising said compounds and to the use of said for manufacturing a medicament for the treatment of pathological conditions or diseases that can improve by modulation of androgen receptor and/or glucocorticoid receptor, selected from cancer, metastasizing cancers, benign prostate hyperplasia, polycystic ovary syndrome (PCOS), hair loss, hirsutism, acne, hypogonadism, muscle wasting diseases, cachexia, Cushing's syndrome, anti-psychotic drug induced weight gain, obesity, post-traumatic stress disorder and alcoholism.

INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR

The present application discloses an indole as represented by formula (I) used as a CRTH2 inhibitor, and a pharmaceutically acceptable salt or tautomer of the indole, and an application of same in treating a disease related to a CRTH2 receptor.

Imidazole-containing condensed tricyclic compound and application thereof

The invention discloses an imidazole-containing condensed tricyclic compound adopting the structure as shown in the formula (I) or pharmaceutically acceptable salts, stereisomers or prodrug molecules thereof. The imidazole-containing condensed tricyclic compound has the IDO1 activity regulation function, can enhance T-cell activation through blocking immune checkpoints IDO1, is used for treating IDO1-mediated immunosuppression, and therefore, can become an effective medicine for treating malignant tumors. When used together with checkpoint protein anti-body drugs or other anti-cancer drugs, the imidazole-containing condensed tricyclic compound can enhance the anti-cancer effect. Meanwhile, the imidazole-containing condensed tricyclic compound has the potential of effectively treating IDO1 abnormity related immunosuppressive diseases and has a high application value.